(R)-Avanafil

(R)-Avanafil (CAS No.: 1638497-26-3) is a synthetic small molecule belonging to the phosphodiesterase inhibitor class and is primarily categorized as a selective phosphodiesterase type 5 inhibitor for mechanistic pharmacology and translational discovery research, where it is used to investigate cyclic nucleotide signaling regulation through competitive inhibition of PDE5 and consequent modulation of the nitric oxide soluble guanylate cyclase cyclic GMP axis, with reported in vitro inhibitory potency in the nanomolar range and specifically around low single digit nanomolar activity for PDE5, supporting its utility as a reference comparator in selectivity profiling, target engagement studies, and pathway focused assay development; in biomedical research settings, this compound is commonly applied to cell based systems that examine vascular smooth muscle associated signaling, cyclic GMP dependent protein kinase responses, and downstream phosphorylation patterns, as well as to preclinical animal models designed to interrogate pharmacodynamic effects of PDE5 pathway perturbation and to benchmark structure activity relationships within PDE directed discovery programs, while experimental concentrations or administered doses are typically determined by assay format, model characteristics, and study objectives in accordance with standard laboratory safety and nonclinical research use practices.